

Research Infrastructures and COVID-19 Research

ACCELERATE is funded by the European Union Framework Programme for Research and Innovation Horizon 2020, under grant agreement 731112

Research Infrastructures and COVID-19 Research

Responses to the questionnaire

ERINHA

European Research Infrastructure on Highly Pathogenic Agents (ERINHA) provides access to Europe's top high containment research facilities to advance research on highly infectious diseases by developing more effective diagnostics, therapeutics, and vaccines. This cooperative scheme allows rapid testing of new or repurposed drugs, optimized in vivo efficacy studies, and opens the door to SME companies, industry, and public researchers, to test their innovative products against existing and emerging infectious diseases.

SERVICE/S IMPLEMENTED

High containment (BSL3 & BSL4) and complementary facilities for
in - vitro studies (Virus propagation and quantification; Standard virologic assays; high throughput screening assays, diagnostic development and testing capacity)
in-vivo studies (Various small animal disease models, NHP disease model, In vivo virologic and immunological assays; pre-clinical vaccines and therapeutics testing)

- **What stage in COVID-19 intervention your RI is addressing?**

Pre-clinical research (capacity for pre-clinical testing of vaccine, therapeutics and diagnostics; drug repurposing...), as well as support functions (protocol set-up, project management)

- **Instruments/databases involved:**

High-containment (BSL3 & BSL4) and complementary facilities

- **How is the proposal submitted?**

to the Central Coordinating Unit (CCU) at contact(at)erinha.eu

- **Who evaluates the proposal?**

Executive Board of ERINHA & Independant Advisory Board

- **Is the submission continuous, or linked to a deadline?**

Continuous

- **What is the estimated time from the submission to the access / service provision?**

It depends on type of project/service

CHARACTERISTICS OF THE ACCESS

Restrictions: No

In the case of analytical facilities, modality of access allowed: Remote and on-site access

Comment for remote access only: ERINHA

Analytical Facilities: If on-site access is allowed, is mobility support available?	NO
All RIs: Is the access free for non-proprietary research?	NO
All RIs: Is commercial access available at reduced prices?	NO
Analytical Facilities: Are there limitations regarding the type of samples?	NO
Analytical Facilities: Are there special requirements for shipment of the samples?	YES
Analytical Facilities: Are there specific requirements regarding the preparation or handling of the samples?	YES

Additional comments related to the questions above:

ACCESSIBILITY OF THE PUBLICATION AND DATA

Is there any requirement to publish in open access journals?	YES
Is the data generated associated to metadata and is it publicly available?	NO
If yes, what is the embargo period?	It depends on data and institution
Where is the data or metadata published? (e.g. in the institution's catalogue, in other open data repositories, etc).	It depends on data and facility/institution
Do you have further comments about data or metadata?	